Ceribell, Inc. CBLL recently announced that it has received FDA clearance for the Clarity algorithm for use in pediatric patients. This breakthrough expands the utility of Ceribell’s rapid ...

Powered by Clarity, the Ceribell System will enable rapid, bedside detection, diagnosis and treatment of non-convulsive seizures in children experiencing neurological emergencies SUNNYVALE, Calif., ...

Currently, CSE is treated using an algorithm which incorporates 10 min intervals between treatments. Second-line treatment is given when CSE persists either after two doses of the first-line treatment ...

Objective: To compare the management of first afebrile seizures with internationally recognized standards in an Irish tertiary paediatric setting. Methods: Records of first afebrile seizure presenting ...

Febrile seizures are a common event and a frequent cause for pediatric Emergency Department (ED) visits. A febrile seizure is defined as a seizure in a child between 6-60 months of age that is ...

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ...

Based on Ceribell’s assessment, its Clarity algorithm now provides coverage across the largest age range ever addressed by a seizure detection technology. This offers hospitals, particularly emergency ...